Stewart D. Clark, Ph.D. - Publications

Affiliations: 
University of California, Irvine, Irvine, CA 
Area:
Molecular neurobiology

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Clark SD, Kenakin TP, Gertz S, Hassler C, Gay EA, Langston TL, Reinscheid RK, Runyon SP. Identification of the first biased NPS receptor agonist that retains anxiolytic and memory promoting effects with reduced levels of locomotor stimulation. Neuropharmacology. PMID 28267583 DOI: 10.1016/j.neuropharm.2017.03.001  0.8
2015 Bensaid M, Michel PP, Clark SD, Hirsch EC, François C. Role of pedunculopontine cholinergic neurons in the vulnerability of nigral dopaminergic neurons in Parkinson's disease. Experimental Neurology. PMID 26571193 DOI: 10.1016/j.expneurol.2015.11.004  0.8
2015 Likhite N, Jackson CA, Liang MS, Krzyzanowski MC, Lei P, Wood JF, Birkaya B, Michaels KL, Andreadis ST, Clark SD, Yu MC, Ferkey DM. The protein arginine methyltransferase PRMT5 promotes D2-like dopamine receptor signaling. Science Signaling. 8: ra115. PMID 26554819 DOI: 10.1126/scisignal.aad0872  0.8
2015 MacLaren DA, Markovic T, Daniels D, Clark SD. Enhanced consumption of salient solutions following pedunculopontine tegmental lesions. Neuroscience. 284: 381-99. PMID 25305665 DOI: 10.1016/j.neuroscience.2014.09.075  0.8
2015 Mueller LE, Kausch MA, Markovic T, MacLaren DA, Dietz DM, Park J, Clark SD. Intra-ventral tegmental area microinjections of urotensin II modulate the effects of cocaine. Behavioural Brain Research. 278: 271-9. PMID 25264578 DOI: 10.1016/j.bbr.2014.09.036  0.8
2015 Cyr M, Parent MJ, Mechawar N, Rosa-Neto P, Soucy JP, Clark SD, Aghourian M, Bedard MA. Deficit in sustained attention following selective cholinergic lesion of the pedunculopontine tegmental nucleus in rat, as measured with both post-mortem immunocytochemistry and in vivo PET imaging with [¹⁸F]fluoroethoxybenzovesamicol. Behavioural Brain Research. 278: 107-14. PMID 25257103 DOI: 10.1016/j.bbr.2014.09.021  0.8
2014 MacLaren DA, Markovic T, Clark SD. Assessment of sensorimotor gating following selective lesions of cholinergic pedunculopontine neurons. The European Journal of Neuroscience. 40: 3526-37. PMID 25208852 DOI: 10.1111/ejn.12716  0.8
2014 Belaid H, Adrien J, Laffrat E, Tandé D, Karachi C, Grabli D, Arnulf I, Clark SD, Drouot X, Hirsch EC, François C. Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment and pedunculopontine nucleus lesion. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 9124-33. PMID 24990932 DOI: 10.1523/JNEUROSCI.0181-14.2014  0.8
2014 Cyr M, Parent MJ, Mechawar N, Rosa-Neto P, Soucy JP, Aliaga A, Kostikov A, Maclaren DA, Clark SD, Bedard MA. PET imaging with [¹⁸F]fluoroethoxybenzovesamicol ([¹⁸F]FEOBV) following selective lesion of cholinergic pedunculopontine tegmental neurons in rat. Nuclear Medicine and Biology. 41: 96-101. PMID 24267056 DOI: 10.1016/j.nucmedbio.2013.10.004  0.8
2013 Gancarz-Kausch AM, Schroeder GL, Panganiban C, Adank D, Humby MS, Kausch MA, Clark SD, Dietz DM. Transforming growth factor beta receptor 1 is increased following abstinence from cocaine self-administration, but not cocaine sensitization. Plos One. 8: e83834. PMID 24386286 DOI: 10.1371/journal.pone.0083834  0.8
2013 Grabli D, Karachi C, Folgoas E, Monfort M, Tande D, Clark S, Civelli O, Hirsch EC, François C. Gait disorders in parkinsonian monkeys with pedunculopontine nucleus lesions: a tale of two systems. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 33: 11986-93. PMID 23864685 DOI: 10.1523/JNEUROSCI.1568-13.2013  0.8
2011 Clark SD, Duangdao DM, Schulz S, Zhang L, Liu X, Xu YL, Reinscheid RK. Anatomical characterization of the neuropeptide S system in the mouse brain by in situ hybridization and immunohistochemistry. The Journal of Comparative Neurology. 519: 1867-93. PMID 21452235 DOI: 10.1002/cne.22606  0.8
2011 Okamura N, Garau C, Duangdao DM, Clark SD, Jüngling K, Pape HC, Reinscheid RK. Neuropeptide S enhances memory during the consolidation phase and interacts with noradrenergic systems in the brain. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 36: 744-52. PMID 21150909 DOI: 10.1038/npp.2010.207  0.8
2010 Si W, Aluisio L, Okamura N, Clark SD, Fraser I, Sutton SW, Bonaventure P, Reinscheid RK. Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortex. Journal of Neurochemistry. 115: 475-82. PMID 20722970 DOI: 10.1111/j.1471-4159.2010.06947.x  0.8
2010 Clark SD, Tran HT, Zeng J, Reinscheid RK. Importance of extracellular loop one of the neuropeptide S receptor for biogenesis and function. Peptides. 31: 130-8. PMID 19874863 DOI: 10.1016/j.peptides.2009.10.015  0.8
2010 Gill RS, Hsiung MS, Sum CS, Lavine N, Clark SD, Van Tol HH. The dopamine D4 receptor activates intracellular platelet-derived growth factor receptor beta to stimulate ERK1/2. Cellular Signalling. 22: 285-90. PMID 19782129 DOI: 10.1016/j.cellsig.2009.09.031  0.8
2009 Duangdao DM, Clark SD, Okamura N, Reinscheid RK. Behavioral phenotyping of neuropeptide S receptor knockout mice. Behavioural Brain Research. 205: 1-9. PMID 19646487 DOI: 10.1016/j.bbr.2009.07.024  0.8
2009 Nagasaki H, Chung S, Dooley CT, Wang Z, Li C, Saito Y, Clark SD, Houghten RA, Civelli O. The pharmacological properties of a novel MCH1 receptor antagonist isolated from combinatorial libraries. European Journal of Pharmacology. 602: 194-202. PMID 19041642 DOI: 10.1016/j.ejphar.2008.10.068  0.8
2008 Jüngling K, Seidenbecher T, Sosulina L, Lesting J, Sangha S, Clark SD, Okamura N, Duangdao DM, Xu YL, Reinscheid RK, Pape HC. Neuropeptide S-mediated control of fear expression and extinction: role of intercalated GABAergic neurons in the amygdala. Neuron. 59: 298-310. PMID 18667157 DOI: 10.1016/j.neuron.2008.07.002  0.8
2007 Clark SD, Alderson HL, Winn P, Latimer MP, Nothacker HP, Civelli O. Fusion of diphtheria toxin and urotensin II produces a neurotoxin selective for cholinergic neurons in the rat mesopontine tegmentum. Journal of Neurochemistry. 102: 112-20. PMID 17419804 DOI: 10.1111/j.1471-4159.2007.04529.x  0.8
2005 Nothacker HP, Clark S. From heart to mind: The urotensin II system and its evolving neurophysiological role Febs Journal. 272: 5694-5702. PMID 16279935 DOI: 10.1111/j.1742-4658.2005.04983.x  0.8
2005 Clark SD, Nothacker HP, Blaha CD, Tyler CJ, Duangdao DM, Grupke SL, Helton DR, Leonard CS, Civelli O. Urotensin II acts as a modulator of mesopontine cholinergic neurons. Brain Research. 1059: 139-48. PMID 16183039 DOI: 10.1016/j.brainres.2005.08.026  0.8
2005 Huitron-Resendiz S, Kristensen MP, Sánchez-Alavez M, Clark SD, Grupke SL, Tyler C, Suzuki C, Nothacker HP, Civelli O, Criado JR, Henriksen SJ, Leonard CS, de Lecea L. Urotensin II modulates rapid eye movement sleep through activation of brainstem cholinergic neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 5465-74. PMID 15944374 DOI: 10.1523/JNEUROSCI.4501-04.2005  0.8
2005 Van Craenenbroeck K, Clark SD, Cox MJ, Oak JN, Liu F, Van Tol HH. Folding efficiency is rate-limiting in dopamine D4 receptor biogenesis. The Journal of Biological Chemistry. 280: 19350-7. PMID 15755724 DOI: 10.1074/jbc.M414043200  0.8
2004 Xu YL, Reinscheid RK, Huitron-Resendiz S, Clark SD, Wang Z, Lin SH, Brucher FA, Zeng J, Ly NK, Henriksen SJ, de Lecea L, Civelli O. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron. 43: 487-97. PMID 15312648 DOI: 10.1016/j.neuron.2004.08.005  0.8
2001 Clark SD, Nothacker HP, Wang Z, Saito Y, Leslie FM, Civelli O. The urotensin II receptor is expressed in the cholinergic mesopontine tegmentum of the rat. Brain Research. 923: 120-7. PMID 11743979 DOI: 10.1016/S0006-8993(01)03208-5  0.8
Show low-probability matches.